Guía de cribado del cáncer de cuello de útero en España, 2014

Bladé, Aureli Torné; Saladrigues, Marta del Pino; Gimferrer, Maite Cusidó; Quitllet, Francesc Alameda; Ortiz, Daniel Andía; Piqué, Xavier Castellsagué; Bordoy, Javier Cortés; Carreño, Rosario Granados; Troyas, Rosa María Guarch; Rubio, Belén Lloveras; Lubrano, Amina; Martínez‐Escoriza, Juan Carlos; Majà, Jaume Ordi; Puig-Tintoré, Luis M.; Mena, Mar Ramírez; Llongueras, Silvia de Sanjosé; Cardoso, Rafael Torrejón; José, Xavier Bosch; Piris, Miguel Á.; Costa, Julio Rodríguez; Delgado, Rafael Comino; Vicens, Josep Maria Laïlla; Sebastià, Jordi

doi:10.1016/s0304-5013(14)73068-7

Cited by 24 publications

(5 citation statements)

References 136 publications

(234 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings related to cervical cytology or Pap smear closely paralleled established evidence [11] while also shedding light on certain distinctions, such as a reduced screening coverage and an elevated proportion of abnormal results in contrast to Spain's national data [60]. Comparable patterns were evident in HPV PCR testing, with the younger vaccinated cohorts displaying elevated rates of positive infections.…”

Section: Discussionsupporting

confidence: 63%

Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case–Control Study

Colomé-Ceballos,

Clua-Espuny,

Ceballos-García

et al. 2023

Vaccines

View full text Add to dashboard Cite

HPV vaccination coverage rates can vary depending on several factors. The main objective of this study is to identify possible independent prognostic factors that have an impact on HPV vaccination in a rural community, specifically related to sexual and reproductive health. A case–control, retrospective, community-based study was carried out on women aged 15 to 40 in the primary health centers of Southern Catalonia’s Terres de l’Ebre region, Spain, from 1 January 2020 to 31 December 2022. A random sample of 520 women with an average age of 29.3 (SD 7.8) years old was included in the study. Independent prognostic factors: age OR 0.680 (95% CI: 0.635–0.729, p < 0.001), immigrant origin OR 0.215 (95% CI: 0.109–0.422, p < 0.001), and HPV PCR OR 7.402 (95% CI: 2.504–21.880, p < 0.001). The variables that showed a barrier effect for HPV vaccination were age (OR 0.680, 95% CI 0.635–0.729, p < 0.001), and immigrant origin (OR 0.215, 95% CI 0.109–0.422, p < 0.001). The variable that showed a facilitating effect for HPV vaccination was HPV PCR (OR 7.402, 95% CI 2.504–21.880, p < 0.001).

show abstract

Section: Discussionsupporting

confidence: 63%

Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case–Control Study

Colomé-Ceballos,

Clua-Espuny,

Ceballos-García

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Women referred to our colposcopic unit at Hospital Clínico San Carlos, Madrid, Spain between January 2011 and June 2020 were recruited. We followed the Spanish Society of Cervical Pathology and Colposcopy (AEPCC) guidelines and indications to set the inclusion criteria [4,12], and those recommendations were still followed according to new updates to the guidelines [13]. These recommendations suggest that an immediate HSIL/CIN3+ risk of 5% or more should be used as the threshold to perform a colposcopy.…”

Section: Methodsmentioning

confidence: 99%

Analysis of New Colposcopy Techniques in the Diagnosis and Evolution of SIL/CIN: Comparison of Colposcopy with the DSI System (COLPO-DSI Study)

González González,

Ramírez Mena,

Calvo Torres

et al. 2023

JPM

View full text Add to dashboard Cite

Compared with conventional colposcopy, colposcopy assisted by DSI-map increases the detection of HSIL/CIN2+ and might help to identify the lesions more likely to regress. Introduction: Comparison of the performance of colposcopy assisted by dynamic spectral imaging (C-DSI) with that of conventional colposcopy (CC) in the diagnosis of cervical intraepithelial neoplasia (HSIL/CIN2 or CIN3). Materials and Methods: A total of 1655 women were referred for colposcopy between 2012 and 2020 and included in the study. Of that total, 973 were examined by the same colposcopist with C-DSI, and 682 with CC. Comparisons between CC and C-DSI were made by using the histological diagnosis performed with a punch biopsy or loop electrosurgical excision procedure (LEEP) as the gold standard. A follow-up study was conducted until 2021 to detect progression to HSIL/CIN2 at 6, 12 and 24 months after first examination. Results: C-DSI provided higher sensitivity for the diagnosis of HSIL/CIN2 or CIN 3 than CC (sensitivity of 76.8% and 86.6% vs. 54.2% and 72.2%, respectively). In negative or ASCUS/LSIL Pap smear results, C-DSI showed higher sensitivity than CC (sensitivity of 66.7% and 61.5% vs. 21.4% and 33.3%, respectively). In contrast, these differences were not observed in high-grade Pap smears. The sensitivity of C-DSI in cases with HPV16/18 infection was stronger than that of CC (73.53% vs. 56.67%). The sensitivity of C-DSI to detect the progression to HSIL/CIN2+ during follow-up was 30, 17.6 and 35.7% at 6, 12 and 24 months, respectively. Conclusions: The present study shows that C-DSI in women referred for colposcopy increases the HSIL/CIN 2–3 detection rate compared to conventional colposcopy. Nevertheless, C-DSI does not seem to be an important tool to predict the evolution of the lesions during follow-up.

show abstract

“…A CINtec® PLUS Cytology tesztet Európa szerte több országban használják a betegek vezetésére, többek között Németországban, Olaszországban, Ausztriában (6), Portugáliá ban és Spanyolországban, ahol a klinikai irányelvbe is belekerült a használata (7,8).…”

Section: A Cintec® Plus Cytology Kettős Festésű Immuncitológiai Tesztunclassified

A new immune-staining procedure for the better diagnosis of HPV associated cervical precancerous condition

íMelczer¹

2019

BVSZ

View full text Add to dashboard Cite

Ismert tény, hogy a HPV-vel kapcsolatos betegségek jelentős egészségügyi terhet jelentenek a társadalom számára. A betegségek azonban megelőzhetők. A közleményben az egyik legfontosabb HPV asszociált rosszindulatú daganatos kórkép, a méhnyakrák megelőzésében elérhető legújabb immunfestési eljárás rövid ismertetésére kerül sor. Ennek széles körű elterjedése hazánkban is segíthet a betegség aggasztó morbiditási és mortalitási adatainak javulásában.

show abstract

Guía de cribado del cáncer de cuello de útero en España, 2014

Cited by 24 publications

References 136 publications

Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case–Control Study

Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case–Control Study

Analysis of New Colposcopy Techniques in the Diagnosis and Evolution of SIL/CIN: Comparison of Colposcopy with the DSI System (COLPO-DSI Study)

A new immune-staining procedure for the better diagnosis of HPV associated cervical precancerous condition

Contact Info

Product

Resources

About